Trevi Therapeutics Inc (TRVI) concluded trading on Thursday at a closing price of $3.60, with 63.75 million shares of worth about $229.5 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 29.96% during that period and on December 12, 2024 the price saw a gain of about 44.58%. Currently the company’s common shares owned by public are about 75.45M shares, out of which, 45.60M shares are available for trading.
Stock saw a price change of 38.46% in past 5 days and over the past one month there was a price change of 20.00%. Year-to-date (YTD), TRVI shares are showing a performance of 168.66% which increased to 188.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.16 but also hit the highest price of $4.00 during that period. The average intraday trading volume for Trevi Therapeutics Inc shares is 519.93K. The stock is currently trading 27.73% above its 20-day simple moving average (SMA20), while that difference is up 21.18% for SMA50 and it goes to 22.63% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Trevi Therapeutics Inc (NASDAQ: TRVI) currently have 75.45M outstanding shares and institutions hold larger chunk of about 41.08% of that.
The stock has a current market capitalization of $276.72M and its 3Y-monthly beta is at 0.97. It has posted earnings per share of -$0.44 in the same period. It has Quick Ratio of 7.38 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TRVI, volatility over the week remained 15.03% while standing at 8.56% over the month.
Stock’s fiscal year EPS is expected to drop by -67.59% while it is estimated to decrease by -1.85% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on Dec-13-24 offering a Buy rating for the stock and assigned a target price range of between $6 and $7.50 to it. Coverage by Leerink Partners stated Trevi Therapeutics Inc (TRVI) stock as an Outperform in their note to investors on September 09, 2024, suggesting a price target of $7 for the stock. On August 30, 2024, Raymond James Initiated their recommendations, while on August 30, 2024, H.C. Wainwright Initiated their ratings for the stock with a price target of $6. Stock get a Buy rating from Rodman & Renshaw on June 13, 2024.
